Relmada Therapeutics (RLMD) Expected to Release Quarterly Earnings on Thursday

Relmada Therapeutics (NASDAQ:RLMD) is anticipated to release its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.21) per share for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Relmada Therapeutics (NASDAQ:RLMD) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.04). On average, analysts expect Relmada Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Relmada Therapeutics Stock Down 0.2%

NASDAQ:RLMD opened at $5.30 on Tuesday. The company’s 50 day moving average price is $6.21 and its 200-day moving average price is $5.91. The stock has a market cap of $555.92 million, a price-to-earnings ratio of -4.86 and a beta of 0.46. Relmada Therapeutics has a 52 week low of $0.55 and a 52 week high of $8.00.

Analysts Set New Price Targets

A number of analysts have commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Relmada Therapeutics in a research report on Thursday, June 18th. HC Wainwright assumed coverage on Relmada Therapeutics in a research report on Thursday, June 18th. They set a “buy” rating and a $12.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $12.00.

Institutional Trading of Relmada Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. bought a new stake in Relmada Therapeutics in the first quarter valued at $33,000. XTX Topco Ltd purchased a new position in Relmada Therapeutics during the second quarter valued at approximately $28,000. Marshall Wace LLP bought a new position in shares of Relmada Therapeutics in the 2nd quarter worth $93,000. Jane Street Group LLC bought a new stake in Relmada Therapeutics in the second quarter worth $69,000. Finally, LMR Partners LLP bought a new position in Relmada Therapeutics during the 2nd quarter valued at approximately $33,000. 45.24% of the stock is currently owned by institutional investors and hedge funds.

Relmada Therapeutics Company Profile

Relmada Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada’s research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications.

Relmada’s lead product candidate, REL-1017 (d-methadone), is being evaluated as a potential rapid-acting and maintenance treatment for major depressive disorder, with clinical studies underway to assess its utility in both acute and long-term settings.